Xeraya Capital
25
42M
17
2.27
7
0.32
5
- Areas of investment
Summary
The company was established in Asia in Malaysia. The main department of described VC is located in the Kuala Lumpur.
Considering the real fund results, this VC is 26 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2016. Despite it in 2019 the fund had an activity. Deals in the range of 10 - 50 millions dollars are the general things for fund. This Xeraya Capital works on 2 percentage points more the average amount of lead investments comparing to the other organizations. The fund is generally included in less than 2 deals every year. The top amount of exits for fund were in 2018.
For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight ViewRay, Acutus Medical, Rapid Micro Biosystems. Among the most popular fund investment industries, there are Health Diagnostics, Therapeutics. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups.
The overall number of key employees were 1.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Xeraya Capital, startups are often financed by OrbiMed, Khosla Ventures, Connecticut Innovations. The meaningful sponsors for the fund in investment in the same round are OrbiMed, OUP (Osage University Partners), Kearny Venture Partners. In the next rounds fund is usually obtained by OrbiMed, Kearny Venture Partners, Deerfield Capital Management.
Investments analytics
Analytics
- Total investments
- 25
- Lead investments
- 7
- Exits
- 5
- Rounds per year
- 2.27
- Follow on index
- 0.32
- Investments by industry
- Biotechnology (21)
- Health Care (10)
- Manufacturing (9)
- Medical Device (7)
- Therapeutics (6) Show 20 more
- Investments by region
-
- United States (22)
- United Kingdom (1)
- Germany (1)
- Singapore (1)
- Peak activity year
- 2020
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 13
- Avg. valuation at time of investment
- 86M
- Group Appearance index
- 1.00
- Avg. company exit year
- 25
- Avg. multiplicator
- 9.48
- Strategy success index
- 0.70
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| eZelleron | 04 May 2008 | Hardware, Internet of Things, Mobile Devices | Seed | 59K | Germany, Saxony, Dresden |
| OncoMyx Therapeutics | 09 Dec 2021 | Biotechnology, Health Diagnostics, Medical, Therapeutics | Early Stage Venture | 50M | United States, Arizona, Phoenix |
| P2 Science | 01 Mar 2017 | Biotechnology, Renewable Energy, Chemical | Early Stage Venture | 9M | United States, Connecticut |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.